Company moves to bigger grounds!, page-124

Admedus will need capital.
When you look at capital requirements to develop,complete trials and bring a pharmaceutical to market, (around 1 billion dollars per product) , then I doubt CC sales will fund the programme for a few years yet.
So despite the company operating frugally ,compared to a large pharmaceutical ,they will need another CR. I do not think that is a bad thing and if phase II vaccine trials are successful it should be oversubscribed and at a much higher SP.
Buying medical stocks is a high risk business as 98% of pharmaceuticals fail. The large pharmaceuticals have to be very discerning and factor this failure rate into the cost of the few successful ones.
Admedus is at a great advantage as they already have a proven technology in CC and now only need total market acceptance which will take time and money.
The uncertainty and risk is if the vaccine trial fails ,will the company be able to attract enough capital to continue marketing CC to profit.